Health Care • Biotechnology: Pharmaceutical Preparations
$1.44 ▼ -0.11
(-7.10%)
MKT CAP: $162.8M • VOL: 5.55M
52W L $0 52W H $2
ROARABLE / RQD
D • 45/100
PIOTROSKI
3 / 9
PDSB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$31.5M | -$36.3M | -$43.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$34.5M | -$37.6M | -$42.9M |
| EBITDA (Normalized) | -$31.5M | -$36.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$27.8M | -$35.0M | -$33.6M |
| Capital Expenditures (CapEx) | $0 | $29.0K | — |
| Free Cash Flow (FCF) | -$27.8M | -$35.1M | -$33.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $26.7M | $41.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $9.3M | $19.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PDSB.